Novacyt announced unaudited consolidated revenues results for the six months ended June 30, 2017. For the six months, Group sales, including the effect of the Primerdesign acquisition, increased 42% to €7.0 million compared with €5.0 a year ago. On a pro-forma basis, Group sales increased 13% at CER compared to first half of 2016 and Group sales increased 16% on a pro-forma basis compared to first half of 2016.

The company is targeting continued sales growth in second half of 2017 through: NOVAprep® – Product registrations throughout 19 countries in South America and further investment in Asia Pacific; Primerdesign – Conversion of business-to-business opportunities; and Lab21 – The launch of new products into multiple territories, including Brazil and America and recovery of key tenders.